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Recent studies suggest that migraine may be associated with gastrointestinal (GI) disor-
ders, including irritable bowel syndrome (IBS), inflammatory bowel syndrome, and celiac
disease. Here, an overview of the associations between migraine and GI disorders is
presented, as well as possible mechanistic links and clinical implications. People who reg-
ularly experience GI symptoms have a higher prevalence of headaches, with a stronger
association with increasing headache frequency. Children with a mother with a history
of migraine are more likely to have infantile colic. Children with migraine are more likely
to have experienced infantile colic compared to controls. Several studies demonstrated
significant associations between migraine and celiac disease, inflammatory bowel dis-
ease, and IBS. Possible underlying mechanisms of migraine and GI diseases could be
increased gut permeability and inflammation. Therefore, it would be worthwhile to inves-
tigate these mechanisms further in migraine patients. These mechanisms also give a
rationale to investigate the effects of the use of pre- and probiotics in migraine patients.
Keywords: celiac disease, colic, gastroparesis, migraine, inflammatory bowel disease, irritable bowel syndrome,
leaky gut, probiotics
INTRODUCTION
Migraine is a common headache disorder with a lifetime preva-
lence of 13% in men and 33% in women (1). There are ictal
(migraine attack) and interictal periods. Migraine is a highly dis-
abling disease with high personal and social costs (2). Migraine
can be considered as a complex neurogenic inflammatory disor-
der (3–5) but the pathophysiology is still not fully understood
(6). It is a disease of the brain, possibly of the brainstem and
is associated with increased synthesis and release of calcitonin
gene related peptide (CGRP). A migraine attack can be blocked
with CGRP antagonists (3, 7, 8). The actual pain is generated by
nociceptors of trigeminal nerve endings in the dura. Low sero-
tonin levels may sensitize the nociceptors of trigeminal neurons
(9). Existing data support that serotonin is low interictal but
increased ictally in migraineurs (10, 11). Ictally serotonin ago-
nist, like triptans and ergotamins, which decrease serotonin are
associated with relief of acute pain (7–9). In contrast tricyclic anti-
depressants and selective serotonin and noradrenaline reuptake
inhibitors, which are associated with increases in serotonin, are
utilized for migraine prevention (11). Migraine attacks can be trig-
gered by intrinsic cerebral factors (CGRP release), nitric oxide like
tri-nitroglycerine, corticotrophin releasing hormone (stress), pro-
inflammatory cytokines, and degranulation of mast cells located
Abbreviations: CGRP, calcitonin gene related peptide; GI, gastrointestinal; IBD,
inflammatory bowel disease; IBS, irritable bowel syndrome; LPS, lipopolysaccha-
rides.
in the dura (1, 3, 8). Migraine has a genetic background, but the
concordance in monozygotic twins is only 20%, indicating the
importance of environmental factors in getting the disease (12).
An environmental factor that may play an important role is
the gut microbiota. The number of bacteria in the human gut
outnumbers the human cells by approximately 10:1 (13). Due
to recent technical developments, studies of the gut microbiota
are no longer dependent on culture techniques, but use high-
throughput sequencing techniques to investigate the intestinal
bacterial species. Over 25 different diseases are currently associated
with alterations in the composition of the gut microbiota. At the
moment, most attention has been given to inflammatory bowel
diseases (IBDs), allergy, diabetes, and obesity (14). Besides gas-
trointestinal (GI) diseases, the gut microbiota as an independent
factor can also contribute to systemic diseases. This can be caused
by the migration of stimulated immune cells, by systemic diffusion
of microbial products or metabolites, or by bacterial translocation
as a result of decreased intestinal barrier function (15).
The brain and the GI tract are strongly connected via neural,
endocrine, and immune pathways (16–18). The communication
occurs in two directions, not only from the brain to the gut but also
the other way around. This recent finding on the role of the gut
microbiota in the gut-brain axis suggests that the gut microbiota
can be associated with brain functions and neurological diseases
like migraine. In this review, associations between migraine and
GI diseases are studied and possible therapeutic consequences are
hypothesized.
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HEADACHE AND GASTROINTESTINAL SYMPTOMS
Not all observational studies are restricted to migraine. The
HEAD-hunt study, for example, looked at the relationship between
GI symptoms and headache, including migraine (19). The study
was a questionnaire-based cross-sectional study among more than
51,000 inhabitants of a county in Norway. The study showed a
higher prevalence of headaches among people who regularly expe-
rience GI symptoms compared to the control group without GI
complaints. The association between headache and GI complaints
increased with increasing headache frequency. All the GI com-
plaints were as common among persons with non-migrainous
headache as among migraine patients. So both migraine and
other types of headaches are more common in people with GI
complaints.
MIGRAINE AND GASTROPARESIS
Gastroparesis is a chronic disorder manifested by delayed emp-
tying of the stomach. Gastroparesis is a relatively common com-
plication of diabetes. In a population of patients with symptoms
of diabetic gastroparesis, the patients with cyclic symptom pat-
terns had a higher incidence of migraine headaches (47 vs. 20%,
p= 0.02) compared to patients without cyclic vomiting pattern
(20). Migraine attacks are associated with delayed gastric emptying
(21). This migraine-associated gastroparesis is a problem for the
treatment of the migraine with oral medicines, like oral triptans
(22). Initially, delayed gastric emptying was found during migraine
attacks, now there are also indications that in the interictal peri-
ods migraine patients have delayed gastric emptying. However, the
studies done so far have been small and inconsistent in their results
(23, 24), so further research in this topic is warranted.
MIGRAINE AND COLIC
Infantile colic is a common cause of inconsolable crying during
the first months of life. It is defined according to criteria by Wessel
as crying and fussing for more than 3 h per day, more than 3 days a
week, and for more than 3 weeks in an otherwise healthy and well-
fed infant (25). It affects many infants, with incidence rates ranging
from 5 to 19% (26). Infantile colic might be caused by abdominal
pain, although other causes cannot be excluded. A few studies have
used probiotics to treat or prevent colic, with variable effects (27,
28). Colic has also been suggested as an early life expression of
migraine, as in a group of 154 infant–mother pairs the children
with a mother with a history of migraine (28 in total) were 2.6
times as likely to have colic as infants without maternal history
of migraine (29). Recently, it has been shown that infants with
abdominal colic have a lower intestinal microbiota diversity and
stability compared to control infants in the first weeks of life (30).
Moreover, children with migraine are more likely to have experi-
enced infantile colic compared with controls (OR ranging from
1.6 to 6.6 between different studies) (31–33). Although long-term
prospective studies have not yet been performed, these different
studies indicate the existence of an association between migraine
and infantile colic.
MIGRAINE AND IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome (IBS) is a functional bowel disorder char-
acterized by abdominal pain, bloating, discomfort, and marked
changes in bowel habits as described in the ROME III criteria
(34). The exact pathophysiology of IBS is not understood yet. IBS
and migraine are both 2–3 times more prevalent in women than
in men (1, 35–37). IBS has been shown to be a disorder with an
increased intestinal permeability and this permeability increases
with more severe IBS symptoms (38).
A study among approximately 125,000 IBS patients, identified
in a large national health insurance database, found a prevalence of
migraine of 60 per 1000 against 22 per 1000 in a control population
from the same database (39). After correction for gender and age,
and stratification of the mean monthly total medical cost, the odds
for being diagnosed with migraine were 60% higher for people in
the IBS cohort compared to people in the non-IBS cohort (39).
Also other studies with smaller sample sizes indicated that 25–50%
of IBS subjects had migraine, whereas it was only 4–19% in con-
trols (40, 41). A meta-analysis showed that overall IBS patients are
at risk to have coexisting headache with an estimated OR of 2.7
(CI 2.3–3.1) (42). Although no distinction between headache and
migraine was made in this study, this suggests higher prevalence
of migraine in IBS patients.
A study in Korean migraine patients revealed high numbers
of functional GI symptoms in migraine patients, of which IBS
related symptoms were the most common (43). Unfortunately,
these numbers were not compared with control subjects, also in
the total population a large percentage of the people fulfill the
Rome III criteria for IBS.
Experimental evidence for an association between IBS and
migraine comes from a study in which an IgG-based elimina-
tion diet was given to migraine patients with IBS. Twenty-one
patients were included in the double blind, randomized, con-
trolled, cross-over clinical trial with usual diet, elimination diet,
and provocation diet (44). Compared with baseline, the elimina-
tion diet was associated with a significant reduction in migraine
attack count, duration and severity. Also a significant reduction
in IBS complaints was observed, demonstrating an association
between the two diseases.
MIGRAINE AND CELIAC DISEASE
In patients who suffer from celiac disease, the immune system
develops an autoimmune reaction against gliadin, the main pro-
tein in gluten. This inflammatory reaction is associated with
intestinal damage, including dysfunction of the tight junctions
resulting in an increased intestinal permeability (45–49). Celiac
disease has been associated with migraine headache in case–
control studies (50, 51). In one study, 14 out of 111 celiac disease
patients (12.6%) reported migraine (50). The prevalence in con-
trols was much lower, only 12 out of 211 controls (5.7%). In
another study, migraine was present in 40 out of 188 celiac disease
patients (21%), compared with 13 out of 178 controls (7%) (51).
Conversely, there are also some indications that celiac disease is
more frequent in migraine patients. One study showed that out of
90 adult migraine patients, 4 had celiac disease (4.4%), as opposed
to only 1 out of the 236 controls (0.4%) (52). A second study in 72
pediatric patients with migraine showed four cases (5.5%) of ele-
vated transglutaminase IgA antibodies. The transglutaminase IgA
antibody level is a reliable indicator for the presence of celiac dis-
ease. Elevated transglutaminase IgA antibodies were found only
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in 1 out of the 147 controls (0.6%) (53). Another study among
87 pediatric migraine patients showed 1 child with celiac disease
(1.1%), compared to 2 out of 543 controls (0.04%) (54). How-
ever, in another study no difference was found in the presence of
celiac disease in 100 children with migraine and 1500 controls,
being 2% for both groups (55). The association between migraine
and celiac disease seems to be stronger in adult patients com-
pared with children, although a direct comparison has not yet
been investigated.
Only one study suggests that migraine in celiac disease patients
may be relieved by treating celiac disease. Until now, the primary
treatment for celiac disease is a gluten-free diet (56). The effect
of a gluten-free diet was investigated in a small study with four
patients with both migraine and celiac disease (52). In one patient
migraine completely resolved. In the other three patients, a reduc-
tion in migraine frequency, duration, and intensity was reported.
This suggests that a gluten-free diet used by celiac disease patients
with migraine may give relief in both celiac disease and migraine.
However, it should be noticed that only four patients were included
in this study. Larger, well-designed studies to confirm these results
are warranted.
MIGRAINE AND INFLAMMATORY BOWEL DISEASE
The two main forms of IBD are ulcerative colitis and Crohn’s
disease (57). These diseases are characterized by defects in the
barrier function of the intestinal epithelial layer and the mucosal
immune system (46, 57). Factors that may trigger IBD are antibi-
otics, non-steroidal anti-inflammatory drugs, stress, and infection.
All these factors decrease the mucosal barrier integrity, modulate
the immune response, and change the luminal microenvironment,
providing the susceptibility to inflammation (58).
Data about possible correlations between migraine and IBD
are scarce. To our knowledge, only two studies investigated the
comorbidity between migraine and IBD. In the first study done by
Ford et al., 100 patients with Crohn’s disease or ulcerative colitis
were selected from the Gastroenterology clinic at the University
of North Carolina (59). The prevalence of migraine in the IBD
patients was 30%. This prevalence rate is higher than the US pop-
ulation basal rate of 18.2% for females and 6.5% for males. In the
Crohn’s disease patients migraine was more prevalent (36%) than
in the ulcerative colitis patients (14.8%) (59). In the second study,
111 patients with IBD were questioned in a survey (51). Prevalence
of self-reported migraine was higher in these subjects compared
with controls (OR 2.66, 95% CI 1.08–6.54). No reports in the lit-
erature were found showing a reduction in migraine frequency or
severity with improvements of inflammatory bowel symptoms.
ROLE FOR GUT BARRIER FUNCTION IN MIGRAINE?
This overview of the literature suggests the existence of a rather
strong relationship between GI disorders and migraine. One of the
links between inflammatory diseases and migraine are enhanced
pro-inflammatory immune responses (60). In intestinal disor-
ders characterized by an increased intestinal permeability like
IBS, IBD, and celiac disease enhanced pro-inflammatory immune
responses have been reported (48, 61, 62). Enhanced levels of
pro-inflammatory cytokines like tumor necrosis factor alpha and
interleukin 1β in serum of migraine patients have been found
during migraine attacks (63). These cytokines can act on the
nociceptors of the trigeminal nerve, causing migraine. Also statis-
tical significant associations have been reported between migraine
and a wide range of inflammatory disorders like asthma, obesity,
metabolic syndrome, allergies, and GI diseases (4, 5, 64–70). A
strong trigger of pro-inflammatory immune responses is the leak-
age of lipopolysaccharides (LPS) from the intestinal lumen into
the circulation. Enhanced levels of LPS can enter the circulation
when the intestinal permeability is increased (leaky gut, Figure 1).
Depending on genetic susceptibility, pro-inflammatory responses
can occur in different parts of the body, e.g., in case of migraine
on the nociceptors of the trigeminal nerve.
Gut permeability and inflammation are bidirectional related,
increased permeability can cause inflammation, but inflamma-
tion can also cause increased gut permeability (71). An increased
gut permeability, and thereby increased translocation of LPS can
be caused by multiple factors, like medicines, exercise, mast cell
activation, high fat diet, stress, etc. (72). The most used method to
measure epithelial barrier function is with the lactulose/mannitol
test. Mannitol is transported via the transcellular pathway whereas
lactulose is absorbed through the paracellular pathway. In case
of increased permeability, more lactulose passes the barrier and
eventually ends up in the urine. Therefore, an increase in intesti-
nal permeability is characterized by an increased ratio of lactu-
lose/mannitol (38, 73). It can be hypothesized that reduction of
the permeability of the intestine results in relief of migraine in
the subgroup of patients in whom intestinal permeability plays a
role in the disease. One specific group might be migraine patients
with food allergies. Subjects with food allergies have an increased
intestinal permeability compared with healthy controls (74). The
role of food allergens in migraine is controversial, as evidence
linking avoiding suspected food triggers with improvement in
migraine is still limited (60). In the 1990s and the first 10 years of
this century, there has been almost no interest in studying the rela-
tionship between migraine and diet (75). However, some recent
studies suggest a role for IgG-mediated food allergy in migraine
(44, 76), a hypothesis that warrants further investigations.
TREATMENT OF MIGRAINE WITH PROBIOTICS?
Probiotics are living microorganisms that have beneficial effects
on the health of the host (77). The most used probiotics are lac-
tobacilli and bifidobacteria. Effects of probiotics are dependent
on the used species and strain. Certain probiotics have shown to
be effective in gut-related diseases, like infectious childhood diar-
rhea (78), the prevention of antibiotic-associated diarrhea (79,
80), and necrotizing enterocolitis in premature infants (81). For
other clinical conditions, like atopic dermatitis, IBD, and IBS the
results from clinical trials have been inconsistent (82, 83). This
can be due to multiple factors like study population, duration,
end-points, etc. An important variable are the different probiotic
strains which are studied, making it difficult to draw conclusions
about probiotics in general for these conditions. One of the pos-
sible working mechanisms of probiotics in the treatment of GI
disorders is strengthening of the intestinal barrier. In vitro as well
as in vivo,probiotics have shown to be able to improve the epithelial
barrier function via different mechanisms (84, 85). Most mecha-
nistic work has been done in cell culture systems or in animal
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models. In a randomized double-blind placebo-controlled cross-
over study in healthy adults, probiotics were able to enhance the
epithelial barrier by changing the location of the tight junctions
proteins in the epithelial layer (86).
As probiotics may play a role in maintaining or improving gut
barrier function in human beings, they can have a beneficial effect
in migraine patients with an enhanced intestinal permeability as
well. So far, no clinical randomized controlled trials have been
published where migraine patients received nutritional therapy
with probiotics. An uncontrolled study reported the effects of
a combination of different probiotics (Lactobacillus acidophilus,
Lactobacillus bulgaricus, Enterococcus faecium, and Bifidobacterium
bifidum) with vitamins, minerals, micronutrients, and herbs in 40
migraine patients (87). At the onset of this study, the participants
had a mean quality of life score of 38 [Medical Outcomes Trust
Migraine Specific Quality of Life (MSQ) Questionnaire] and after
90 days of treatment their mean quality of life score was risen to
76. Sixty percent of the migraine patients experienced almost total
relief from migraine attacks and they reported quality of life scores
between 80 and 100.
CONCLUSION
Next to migraine, other brain diseases have been suggested to be
associated with increased gut permeability, including depression,
autism, and stress (15, 88–90). There is growing interest in the
role of the gut microbiota in these brain diseases. In this review, a
possible route via an increased intestinal permeability is suggested.
There is an accumulation of studies on both migraine and GI dis-
orders (Table 1). However, the findings of some (small) studies
are not supported yet by other independent studies. Nevertheless
FIGURE 1 |The microbiota-gut-brain axis.
Table 1 | Summary of intestinal diseases associated with migraine.
Disease Association
Gastroparesis Present during migraine attacks, possible in interictal periods.
Colic Children of migraine mother have more often colic; children with migraine have more often experienced infantile colic.
Irritable bowel syndrome IBS patients have more often migraine; treatment of IBS might lower migraine.
Celiac disease Celiac patients have higher prevalence of migraine; migraine patients might have more often celiac disease; migraine
in celiac patients may be relieved by gluten-free diet.
Inflammatory bowel disease IBD patients have a higher prevalence of migraine.
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placebo-controlled studies in migraine patients using treatments
directed at increased intestinal permeability are warranted. We
have recently started a study in which permeability of the gut is
measured in migraine patients as well as in controls. We also started
a double blind, placebo-controlled trial to investigate the effect of
a probiotic product on gut permeability as well as severity and
incidence of migraine attacks. Hopefully, these studies provide an
answer to the question if gut permeability plays a role in migraine
patients.
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